No immediate pain relief for the pharmaceutical industry

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 3, 2005, Pages 384-391

  Ahlborn, Heather ^a   Henderson, Stuart ^a   Davies, Nick ^a  

^a IBM   (United Kingdom)

Author keywords

Blockbuster; Genomics; Personalized therapies; Pharmaceutical drug development; Targeted treatments; Xomics

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ATORVASTATIN; BEVACIZUMAB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; ENOXAPARIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUCONAZOLE; GEFITINIB; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; IMATINIB; NATALIZUMAB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; SIMVASTATIN; TRASTUZUMAB; VALDECOXIB;

ANALGESIA; ARTHRITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; HEART INFARCTION; HUMAN; LONG TERM CARE; LUNG CANCER; PRESCRIPTION; REVIEW; SIDE EFFECT; STOMACH HEMORRHAGE; STROKE; SUICIDAL BEHAVIOR;

DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; HUMANS; MODELS, ECONOMIC;

EID: 17844397463     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Stovall S: Momentum's winning force. BusinessWeek Online (2005) January 05. http://businessweek.com/investor/content/jan2005/pi2005 015_8394_pi039.htm
2. Lagorce A: Merck's arthritis resolution. Forbes.com (2003) December 31. http://www.forbes.com/2003/12/31/cx_al_ 1231mrk.html
3. Merck & Co: Merck announces voluntary worldwide withdrawal of Vioxx®. Press Release (2004) September 30. http://www.vioxx.com/rofecoxib/ vioxx/consumer/index.jsp
4. FDA public health advisory. Worsening depression and suicidality in patients being treated with antidepressant medications: US Food and Drug Administration, Rockville, MD, USA (2004). http://www. fda.gov/cder/drug/ antidepressants/AntidepressanstPHA.htm
5. FDA public health advisory: Suicidality in children and adolescents being treated with antidepressant medications: US Food and Drug Administration, Rockville, MD, USA (2004). http://vmm.fda.gov/cder/drug/antidepressants/ SSRIPHA200410.htm
6. Original INDs received calendar years 1986-2004: US Food and Drug Administration, Rockville, MD, USA (2004). http://www.fda.gov /cder/rdmt/Cyindrec.htm
7. CDER number of NDAs received by calendar year: US Food and Drug Administration. Rockville, MD, USA (2004). http://www.fda.gov/cder/rdmt/ numofndareccy.htm
8. Thayer AM: The genomics evolution. Chem Eng News (2003) 81(49):17-26. Overview detailing the impact of genomics to drug discovery.
9. CDER new drug and biologic approval reports: US Food and Drug Administration, Rockville, MD, USA (2004). http://www.fda.gov/cder/rdmt/default. htm
10. Coghlan A: Blockbuster challenge. New Scientist (2004) (2451):54-57. Article which outlines the problems of the blockbuster business model.
11. CDER new molecular entity (NME) drug and new biologic approvals in calendar year 2004: US Food and Drug Administration, Rockville, MD, USA (2004). http://www.fda.gov/cder/rdmt/NMECY2004.htm
12. Arlington S, Barnett S, Davies N, Palo J: Pharma 2010: The threshold of innovation: IBM Business Consulting Services, Manchester, UK (2004). http://www-1.ibm.com/services/us/index.wss/xs/imc/a 1001099 Seminal article detailing the authors' views on targeted treatments.
13. Herper M: The world's best-selling drugs. Forbes.com (2004) March 16. http://www.forbes.com/technology/2004/03/16/cx_mh_0316best selling.html
14. Ginsberg T: Glaxo seeks cease-fire in 'arms race' in sales. Philadelphia Inquirer (2005) February 11.
15. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S. Herman P, Kaye FJ, Lindeman N, Boggon TJ. Naoki K et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350(21):2129-2139.
17. Filmore D: Clinical pharmacogenomics: Almost a reality? Mod Drug Disc (2004) 7(8):41-44.
18. Ruder K: Personalized medicine in cancer: Matching patients and drugs. Genome News Network (2004) October 28. http://www. genomenewsnetwork.org/ articles/2004/10/28/matchingpatients.php?prin t=1
19. O'Kane DJ, Weinshilboum RM, Moyer TP: Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics (2003) 4(1):1-4.
20. Evans WE, Relling MV: Moving towards individualized medicine with pharmacogenomics. Nature (2004) 429(6990):464-468.
21. Kraljevic S, Stambrook PJ, Pavelic K: Accelerating drug discovery: Although the evolution of '-omics' methodologies is still in its infancy, both the pharmaceutical industry and patients could benefit from their implementation in the drug development process. EMBO Rep (2004) 5(9):837-842.
22. Arlington S, Davies N: Powering up the pipeline. Pharmafocus (2003). http://www.pharmafocus.com/cda/focusH/1,2109.22-0-0-0-focus_ feature_detail-0-74296,00. html An additional article outlining the authors' viewpoints.
23. Jhingran AD, Mattos N, Pirahesh H: Information integration: A research agenda. IBM Systems Journal (2002) 41(4):555-562.
24. Pharma 2005: Silicon rally - The race to eR&D: PricewaterhouseCoopers LLP, New York, NY, USA (1999). http://www. pwcglobal.com/gx/eng/about/ind/ pharma/silicon_rally.pdf
25. Davies N, Peakman T: Making the most of your discovery data. Drug Disc World (2004) (Spring):17-23.
26. Atkmson WI: Information avalanche: Enterprise content management. Mod Drug Disc (2004) 7(12):49-50.
27. Draft guidance for industry: Pharmacogenomic data submissions: US Food and Drug Administration, Rockville, MD, USA (2003). http://www.fda.gov/cder/ guidance/5900dft.pdf
28. Lesko L, Woodcock J: Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective. Nat Rev Drug Disc (2004) 3:763-769.
29. Hall SS: Personalized medicine's bitter pill. Technology Review.com (2003) February. http://www.technologyreview.com/articles/03/02/hall0203.asp?p=1